ETx 22
Alternative Names: ETx-22; LY-4101174Latest Information Update: 28 Mar 2024
At a glance
- Originator Emergence Therapeutics
- Developer Eli Lilly and Company
- Class Antineoplastics; Cyclic peptides; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors; RNA polymerase II inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 05 Mar 2024 Phase-I clinical trials in Cancer (Late-stage disease, Second-line therapy or greater, Metastatic disease) in USA (IV) (NCT06238479)
- 12 Jan 2024 Safety and pharmacodynamics data from preclinical trial in Canacer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC - 2023)
- 15 Nov 2023 Heidelberg Pharma Research has patent protection for site-specific ATAC conjugates in Europe